Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease

Next Previous
Search
Trial Profile

Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients with GM2 Gangliosidosis or Niemann-Pick Type C Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nizubaglustat (Primary)
  • Indications GM2 gangliosidoses; Niemann-Pick disease type C; Sandhoff disease; Tay-Sachs disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RAINBOW
  • Sponsors Azafaros

Most Recent Events

  • 20 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Mar 2026.
  • 19 Nov 2024 According to an Azafaros media release, the company will deliver a poster presentation on 6 Feb 2025 at the WORLDSymposium™ 2025, showing an analysis compares data from the RAINBOW and PRONTO studies, illustrating the role of natural history studies in guiding drug development.
  • 19 Nov 2024 According to an Azafaros media release, the company will host a satellite symposium on February 4, 2025 at 12:15, which will provide insights into the results from the RAINBOW study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top